Early Helicobacter pylori Eradication Decreases Risk of Gastric Cancer in Patients With Peptic Ulcer Disease

Division of Gastroenterology, Taichung Veterans General Hospital, Taichung, Taiwan.
Gastroenterology (Impact Factor: 16.72). 09/2009; 137(5):1641-8.e1-2. DOI: 10.1053/j.gastro.2009.07.060
Source: PubMed


Helicobacter pylori (H pylori) is a risk factor for gastric cancer. We investigated whether early H pylori eradication is associated with gastric cancer risk in patients with peptic ulcer diseases.
This nationwide cohort study was based on the Taiwan National Health Insurance Database (NHID), which provided data on 80,255 patients who were hospitalized for the first time between 1997 and 2004 with a primary diagnosis of peptic ulcer diseases and received H pylori eradication therapy. The patient population was divided into early (within 1 year) and late (after 1 year) eradication cohorts; standardized incidence ratios (SIRs) and hazards ratios (HRs) were determined.
There was no significant difference in gastric cancer risk between patients who received early H pylori eradication and the general population (SIR, 1.05; 95% confidence interval [CI]: 0.96-1.14), but late eradication was associated with an increased risk (SIR, 1.36; 95% CI: 1.24-1.49). In gastric ulcer patients who received early eradication, SIRs of gastric cancer decreased from 1.60 at 3-4 years to 1.05 at 7-10 years after hospitalization; the SIRs decreased from 0.57 to 0.33 for duodenal ulcer patients over the same period. Among patients who received late eradication, SIRs decreased from 2.14 to 1.32 for those with gastric ulcers and from 0.90 to 0.66 for those with duodenal ulcers. Early H pylori eradication (HR, 0.77) and frequent aspirin or nonsteroidal anti-inflammatory drug use (HR, 0.65) were independent protective factors for gastric cancer.
Early H pylori eradication is associated with decreased risk of gastric cancer in patients with peptic ulcer diseases.

Download full-text


Available from: Chang-BI Wang, Nov 11, 2015
  • Source
    • "For instance H. pylori infection is associated with a risk to develop gastric cancer. So, early eradication of this bacterium is associated with the decrease risk of gastric cancer in patient with gastric cancer [14]. Similarly vaccination against HPV, and HBV are respectively used to fight cervical cancer and hepatocelular carcinoma [15] [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Medicinal plants have been used particularly in resource poor communities of the African continent as an alternative for the treatment of infectious diseases. Traditional medicine plays a critical role in treatment of chronic debilitating and life threatening conditions and infectious diseases. Cancer is one such condition whose therapeutic intervention is commonly through inexpensive traditional herbal remedies. Increasingly industrialised societies are developing drugs and chemotherapeutics from these traditional herbal plants. Plant biogeography determines the abundance and availability of medicinal plants which in turn determine their use by africango communities. Recent findings of bioactivity and therapeutic potential of plant extracts in cancer and infectious diseases are herein summarized and discussed.
    Full-text · Article · May 2015
  • Source
    • "An increased risk of gastric cancer correlates with a late eradication beyond one year in patients with peptic ulcer. Early H. pylori eradication is therefore suggested as an independent protective factor to reduce the risk of gastric cancer [73]. This result is compatible with a large-scale study and meta-analysis, showing that eradication of H. pylori decreases the development of gastric cancer only among those without precancerous lesion [74] [75] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and aims: To compose upper gastrointestinal bleeding (UGIB) consensus from a nationwide scale to improve the control of UGIB, especially for the high-risk comorbidity group. Methods: The steering committee defined the consensus scope to cover preendoscopy, endoscopy, postendoscopy, and overview from Taiwan National Health Insurance Research Database (NHIRD) assessments for UGIB. The expert group comprised thirty-two Taiwan experts of UGIB to conduct the consensus conference by a modified Delphi process through two separate iterations to modify the draft statements and to vote anonymously to reach consensus with an agreement ≥80% for each statement and to set the recommendation grade. Results: The consensus included 17 statements to highlight that patients with comorbidities, including liver cirrhosis, end-stage renal disease, probable chronic obstructive pulmonary disease, and diabetes, are at high risk of peptic ulcer bleeding and rebleeding. Special considerations are recommended for such risky patients, including raising hematocrit to 30% in uremia or acute myocardial infarction, aggressive acid secretory control in high Rockall scores, monitoring delayed rebleeding in uremia or cirrhosis, considering cycloxygenase-2 inhibitors plus PPI for pain control, and early resumption of antiplatelets plus PPI in coronary artery disease or stroke. Conclusions: The consensus comprises recommendations to improve care of UGIB, especially for high-risk comorbidities.
    Full-text · Article · Aug 2014 · BioMed Research International
  • Source
    • "Early eradication of H. pylori has been proven to reduce the incidence rate of gastric cancer and improve ulcer healing [6], [7]. However, eradication of the pathogen has been difficult due to the limited antibiotics available that can withstand the low pH environment in stomach, or the capability of the drug to penetrate the gastric mucous layers to be in contact with the pathogen. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Helicobacter pylori is the etiological agent for diseases ranging from chronic gastritis and peptic ulcer disease to gastric adenocarcinoma and primary gastric B-cell lymphoma. Emergence of resistance to antibiotics possesses a challenge to the effort to eradicate H. pylori using conventional antibiotic-based therapies. The molecular mechanisms that contribute to the resistance of these strains have yet to be identified and are important for understanding the evolutional pattern and selective pressure imposed by the environment.
    Full-text · Article · Jul 2014 · PLoS ONE
Show more